Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Foghorn Therapeutics (FHTX) Non-Current Debt (2020)

Foghorn Therapeutics has reported Non-Current Debt over the past 1 years, most recently at $19.7 million for Q4 2020.

  • Quarterly results put Non-Current Debt at $19.7 million for Q4 2020, changed N/A from a year ago — trailing twelve months through Dec 2020 was $19.7 million (changed N/A YoY), and the annual figure for FY2020 was $19.7 million, changed.
  • Non-Current Debt for Q4 2020 was $19.7 million at Foghorn Therapeutics, up from $8.8 million in the prior quarter.
  • Over the last five years, Non-Current Debt for FHTX hit a ceiling of $19.7 million in Q4 2020 and a floor of $8.8 million in Q3 2020.